The stock of Rewalk Robotics Ltd (NASDAQ:RWLK) hit a new 52-week low and has $2.35 target or 12.00% below today’s $2.67 share price. The 5 months bearish chart indicates high risk for the $37.91 million company. The 1-year low was reported on Nov, 1 by Barchart.com. If the $2.35 price target is reached, the company will be worth $4.55M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 881,084 shares traded hands or 360.70% up from the average. Rewalk Robotics Ltd (NASDAQ:RWLK) has declined 64.79% since March 30, 2016 and is downtrending. It has underperformed by 67.80% the S&P500.
Analysts await Rewalk Robotics Ltd (NASDAQ:RWLK) to report earnings on November, 3. They expect $-0.57 EPS, down 7.55% or $0.04 from last year’s $-0.53 per share. After $-0.74 actual EPS reported by Rewalk Robotics Ltd for the previous quarter, Wall Street now forecasts -22.97% EPS growth.
Rewalk Robotics Ltd (NASDAQ:RWLK) Ratings Coverage
Out of 3 analysts covering Rewalk Robotics (NASDAQ:RWLK), 1 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 33% are positive. Rewalk Robotics has been the topic of 7 analyst reports since August 10, 2015 according to StockzIntelligence Inc. Zacks upgraded the shares of RWLK in a report on Tuesday, August 25 to “Sell” rating. Piper Jaffray initiated Rewalk Robotics Ltd (NASDAQ:RWLK) on Friday, July 15 with “Overweight” rating. The stock of Rewalk Robotics Ltd (NASDAQ:RWLK) has “Hold” rating given on Tuesday, September 8 by Zacks. The firm earned “Hold” rating on Friday, August 14 by Zacks. The stock has “Buy” rating given by Jefferies on Monday, August 10.
According to Zacks Investment Research, “ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury. The Company’s exoskeletons allow wheelchair-bound individuals with mobility impairments or other medical conditions the ability to stand and walk once again. It offers ReWalk Personal for everyday use to individuals at home and in their communities; and ReWalk Rehabilitation for exercise and therapy to individuals with lower limb disabilities in the clinical rehabilitation environment. ReWalk Robotics Ltd. is headquartered in Yokneam Ilit, Israel.”
More notable recent Rewalk Robotics Ltd (NASDAQ:RWLK) news were published by: 247Wallst.com which released: “ReWalk Robotics Slides on Secondary Offering” on October 27, 2016, also Globenewswire.com with their article: “ReWalk Robotics to Discuss 2016 Third Quarter Financial Results on November 3 …” published on October 25, 2016, Prnewswire.com published: “ReWalk Announces Launch of 522 Post-Market Study with Stanford University …” on August 02, 2016. More interesting news about Rewalk Robotics Ltd (NASDAQ:RWLK) were released by: Prnewswire.com and their article: “German Social Court Ruling Deems ReWalk Exoskeleton Medically Necessary as …” published on August 04, 2016 as well as Businesswire.com‘s news article titled: “Robbins Arroyo LLP: ReWalk Robotics Ltd. (RWLK) Misled Shareholders According …” with publication date: October 03, 2016.
RWLK Company Profile
ReWalk Robotics Ltd., incorporated on June 20, 2001, is a medical device company. The Firm is engaged in designing, developing and commercializing exoskeletons that allow wheelchair-bound individuals with mobility impairments or other medical conditions the ability to stand and walk. It offers ReWalk, an exoskeleton that uses its tilt-sensor technology, and an on-board computer and motion sensors to drive motorized legs that power movement. ReWalk creates focus on people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, who have the use of their upper bodies and arms. It offers various products, which include ReWalk Personal and ReWalk Rehabilitation.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.